Tag Archive for: life sciences

Sector updates in September

Investment firms  ARCH Venture Partners has raised $3b to support the founding and growth of early-stage biotechnology companies.  Asabys Partners has raised €180m to invest in biopharma, medical device and digital health companies   Headline, formerly known as e.ventures and BV Capital, has raised $865m to invest in varying sectors including health and deep tech   All […]

Sofinnova Partners appoints Karl Naegler as Partner

Seasoned investor with 20 years of experience and a strong track record strengthens VC’s leadership in early-stage life science investments PARIS, France – September 10, 2024 — Sofinnova Partners (“Sofinnova”), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of Karl Naegler as Partner. This strategic hire also […]

The ‘must-attend’ Healthcare conferences Autumn / Winter 2024

With the summer holidays drawing to a close, now is the time to be organising your conference calendar to maximise the opportunities these major events in life sciences present. Secure your travel and accommodation while prices are attractive, and availability is high.  As an official partner to many of the top events, Optimum is pleased […]

Weekly wrap-up: Novo Holdings leads $105 million financing of Magenta Medical to support FDA approval for world’s smallest heart pump

Novo Holdings, a leading life science investor, on Tuesday announced that it has led a $105 million financing in Magenta Medical, developer of the Elevate™ System, the world’s smallest heart pump. The financing will be used to advance the company’s US clinical programs in multiple mechanical circulatory support (MCS) indications and to secure the first […]

Death cap poison: the latest weapon in the fight against cancer

The death cap mushroom is feared throughout much of the world because of the deadly toxin it contains, amanitin. But could the poison reputedly used by Agrippina to murder her husband, the Roman emperor Claudius, be used to destroy cancer, asks Richard Staines. Known to modern science as an inhibitor of RNA polymerase II, alpha-Amanitin […]